Venofer Related Published Studies
Well-designed clinical trials related to Venofer (Iron Sucrose)
Ferumoxytol: a new era of iron deficiency anemia treatment for patients with chronic kidney disease. [2011.11]
FERGIcor, a randomized controlled trial on ferric carboxymaltose for iron deficiency anemia in inflammatory bowel disease. [2011.09]
Impact of iron treatment on immune effector function and cellular iron status of circulating monocytes in dialysis patients. [2011.03]
Iron sucrose with and without recombinant erythropoietin for the treatment of severe postpartum anemia: a prospective, randomized, open-label study. [2011.02]
Proteinuria induced by parenteral iron in chronic kidney disease--a comparative randomized controlled trial. [2011.01]
Role of perioperative intravenous iron therapy in elderly hip fracture patients: a single-center randomized controlled trial. [2011.01]
Effects of intravenous iron combined with low-dose recombinant human erythropoietin on transfusion requirements in iron-deficient patients undergoing bilateral total knee replacement arthroplasty. [2011.01]
High incidence of iron depletion and restless leg syndrome (RLS) in regular blood donors: intravenous iron sucrose substitution more effective than oral iron. [2010.11]
Proteinuria Induced by Parenteral Iron in Chronic Kidney Disease--A Comparative Randomized Controlled Trial. [2010.09.28]
Oxidative stress in hemodialysis patients receiving intravenous iron therapy and the role of N-acetylcysteine in preventing oxidative stress. [2010.09]
Role of perioperative intravenous iron therapy in elderly hip fracture patients: a single-center randomized controlled trial. [2010.07.12]
Randomized clinical trial on acute effects of i.v. iron sucrose during haemodialysis. [2010.03]
Blood transfusion reduction with intravenous iron in gynecologic cancer patients receiving chemotherapy. [2010.03]
Maintenance of elevated versus physiological iron indices in non-anaemic patients with chronic kidney disease: a randomized controlled trial. [2010.03]
Comparison of parenteral iron sucrose and ferric chloride during erythropoietin therapy of haemodialysis patients. [2010.02]
Efficacy and safety of ferric carboxymaltose in correcting iron-deficiency anemia: a review of randomized controlled trials across different indications. [2010]
Effects of iron supplementation and depletion on hypoxic pulmonary hypertension: two randomized controlled trials. [2009.10.07]
Randomized clinical trial of preoperative intravenous iron sucrose to reduce blood transfusion in anaemic patients after colorectal cancer surgery. [2009.10]
Rapid recurrence of IBD-associated anemia and iron deficiency after intravenous iron sucrose and erythropoietin treatment. [2009.06]
Iron prophylaxis in pregnancy: intravenous route versus oral route. [2009.06]
[Intravenous iron sucrose in maintenance dialysis patients with renal anemia: a clinical study] [2009.02.24]
A randomized, double-blind, placebo-controlled trial of intravenous iron sucrose in restless legs syndrome. [2009.02]
Ferric carboxymaltose: a review of its use in iron-deficiency anaemia. [2009]
Safety and usefulness of intravenous iron sucrose in the management of preoperative anemia in patients with menorrhagia: a phase IV, open-label, prospective, randomized study. [2009]
Lipid peroxidation products formation with various intravenous iron preparations in chronic kidney disease. [2009]
Intravenous iron sucrose is superior to oral iron sulphate for correcting anaemia and restoring iron stores in IBD patients: A randomized, controlled, evaluator-blind, multicentre study. [2009]
Intravenous iron exacerbates oxidative DNA damage in peripheral blood lymphocytes in chronic hemodialysis patients. [2008.09]
Intravenous iron sucrose in peritoneal dialysis patients with renal anemia. [2008.03]
A randomized, double-blind, placebo-controlled trial of intravenous iron sucrose in restless legs syndrome. [2008.02.13]
Effect of intravenous iron sucrose on exercise tolerance in anemic and nonanemic patients with symptomatic chronic heart failure and iron deficiency FERRIC-HF: a randomized, controlled, observer-blinded trial. [2008.01.15]
Intravenous iron sucrose in Chinese hemodialysis patients with renal anemia. [2008]
A 12-week randomised study comparing intravenous iron sucrose versus oral ferrous sulphate for treatment of postpartum anemia. [2008]
Intravenous iron reduces NT-pro-brain natriuretic peptide in anemic patients with chronic heart failure and renal insufficiency. [2007.10.23]
Effect of intravenously administered iron sucrose on the prevention of anemia in the cervical cancer patients treated with concurrent chemoradiotherapy. [2007.04]
Rationale and design of the IRON-HF study: a randomized trial to assess the effects of iron supplementation in heart failure patients with anemia. [2007.02]
Intravenous versus oral iron therapy for postpartum anaemia. [2006.11]
Impact of iron sucrose therapy on leucocyte surface molecules and reactive oxygen species in haemodialysis patients. [2006.10]
Intravenous iron alone for the treatment of anemia in patients with chronic heart failure. [2006.09.19]
Effect of intravenous iron sucrose in peritoneal dialysis patients who receive erythropoiesis-stimulating agents for anemia: a randomized, controlled trial. [2006.05]
Role of parenteral iron in transfusion requirements after total hip replacement. A pilot study. [2006.04]
Iron sucrose augments homocysteine-induced endothelial dysfunction in normal subjects. [2006.02]
Intravenous iron and recombinant erythropoietin for the treatment of postoperative anemia. [2006.01]
Intravenous versus oral iron for treatment of anemia in pregnancy: a randomized trial. [2005.12]
A randomized, controlled trial comparing IV iron sucrose to oral iron in anemic patients with nondialysis-dependent CKD. [2005.12]
Intravenous iron increases labile serum iron but does not impair forearm blood flow reactivity in dialysis patients. [2005.12]
Intravenous iron sucrose versus oral iron supplementation for the treatment of iron deficiency anemia in patients with inflammatory bowel disease--a randomized, controlled, open-label, multicenter study. [2005.11]
[Post-haemodilution anaemia in paediatric cardiac surgery: benefit of intravenous iron therapy] [2005.10]
Oral ferrous fumarate or intravenous iron sucrose for patients with inflammatory bowel disease. [2005.09]
Effect of sucrose containing iron (II) on dental biofilm and enamel demineralization in situ. [2005.03]
Comparison of intravenous iron sucrose to oral iron in the treatment of anemic patients with chronic kidney disease not on dialysis. [2005]
Parenteral iron therapy in treatment of anemia in end-stage renal disease patients: a comparative study between iron saccharate and gluconate. [2005]
Oxidative stress from rapid versus slow intravenous iron replacement in haemodialysis patients. [2004.08]
Oxidative stress and renal injury with intravenous iron in patients with chronic kidney disease. [2004.06]
High-dose parenteral iron sucrose depresses neutrophil intracellular killing capacity. [2003.08]
Iron deficiency and anaemia in pregnancy: modern aspects of diagnosis and therapy. [2002.11]
Iron therapy in iron deficiency anemia in pregnancy: intravenous route versus oral route. [2002.03]
A randomized, controlled parallel-group trial on efficacy and safety of iron sucrose (Venofer) vs iron gluconate (Ferrlecit) in haemodialysis patients treated with rHuEpo. [2001.06]
A randomized study of oral vs intravenous iron supplementation in patients with progressive renal insufficiency treated with erythropoietin. [2001.05]
The effect of i.v. iron alone or in combination with low-dose erythropoietin in the rapid correction of anemia of chronic renal failure in the predialysis period. [2001.03]
Efficacy and safety of intravenously administered iron sucrose with and without adjuvant recombinant human erythropoietin for the treatment of resistant iron-deficiency anemia during pregnancy. [2001.03]
Effect of intravenous iron supplementation on erythropoiesis in erythropoietin-treated premature infants. [2001.01]
Clinical characteristic of parenteral iron supplementation in hemodialysis patients receiving erythropoietin therapy. [2000.10]
Intravenous versus oral iron supplementation for preoperative stimulation of hemoglobin synthesis using recombinant human erythropoietin. [2000.08]
Effectiveness of recombinant erythropoietin and iron sucrose vs. iron therapy only, in patients with postpartum anaemia and blunted erythropoiesis. [2000.02]
Oral or intravenous iron as an adjuvant to autologous blood donation in elective surgery: a randomized, controlled study. [1999.05]
Sequential treatment of anemia in ulcerative colitis with intravenous iron and erythropoietin. [1999]
The effect of intravenous iron on the reticulocyte response to recombinant human erythropoietin. [1997.08]
The efficiency of fractionated parenteral iron treatment in CAPD patients. [1997]
A comparison of oral and intravenous iron supplementation in preterm infants receiving recombinant erythropoietin. [1996.08]
Well-designed clinical trials possibly related to Venofer (Iron Sucrose)
Effect of single recombinant human erythropoietin injection on transfusion requirements in preoperatively anemic patients undergoing valvular heart surgery. [2011.11]
[Intravenous treatment of postpartum anemia with trivalent ferrum preparation] [2007.05]
Epoetin alfa plus autologous blood donation and normovolemic hemodilution in patients scheduled for orthopedic or vascular surgery. [1996.04]
Epoetin alfa for autologous blood donation in patients with rheumatoid arthritis and concomitant anemia. [1996.04]
Other research related to Venofer (Iron Sucrose)
Iron sucrose versus oral iron therapy in pregnancy anemia. [2012]
Is intravenous iron sucrose the treatment of choice for pregnant anemic women? [2012]
Non-transferrin bound iron, cytokine activation and intracellular reactive oxygen species generation in hemodialysis patients receiving intravenous iron dextran or iron sucrose. [2011.08]
Safety profiles of total dose infusion of low-molecular-weight iron dextran and high-dose iron sucrose in renal patients. [2011.07]
Intravenous iron sucrose for children with iron deficiency failing to respond to oral iron therapy. [2011.04]
Total dose infusion of intravenous iron in patients with chronic kidney disease receiving haemodialysis. [2011.03]
Impact of C-reactive protein on absolute reticulocyte count in haemodialysis patients: the role of iron status. [2011.03]
Efficacy of intravenous iron for treating postpartum anemia in low-resource African countries: a pilot study in Malawi. [2011.01]
Assessment of the extent of oxidative stress induced by intravenous ferumoxytol, ferric carboxymaltose, iron sucrose and iron dextran in a nonclinical model. [2011]
Differences in spontaneously reported hypersensitivity and serious adverse events for intravenous iron preparations: comparison of Europe and North America. [2011]
Comparison of adverse-event profiles of intravenous low-molecular-weight iron dextran and iron sucrose in peritoneal dialysis patients. [2011]
Proteinuria induced by parenteral iron in chronic kidney disease--a comparative
randomized controlled trial. [2011]
Impact of iron treatment on immune effector function and cellular iron status of
circulating monocytes in dialysis patients. [2011]
Postoperative high-dose intravenous iron sucrose with low dose erythropoietin therapy after total hip replacement. [2010.12]
The health care cost of intravenous iron treatment in IBD patients depends on the economic evaluation perspective. [2010.10]
Impact of iron treatment on immune effector function and cellular iron status of circulating monocytes in dialysis patients. [2010.09.08]
Use of parenteral iron products and serious anaphylactic-type reactions. [2010.09]
Randomized evaluation of efficacy and safety of ferric carboxymaltose in patients with iron deficiency anaemia and impaired renal function (REPAIR-IDA): rationale and study design. [2010.07]
High incidence of iron depletion and restless leg syndrome (RLS) in regular blood donors: intravenous iron sucrose substitution more effective than oral iron. [2010.06.24]
Iron replacement therapy: assessing today's options to prepare for bundling. [2010.02]
Randomized evaluation of efficacy and safety of ferric carboxymaltose in patients
with iron deficiency anaemia and impaired renal function (REPAIR-IDA): rationale
and study design. [2010]
Oxidative stress in hemodialysis patients receiving intravenous iron therapy and
the role of N-acetylcysteine in preventing oxidative stress. [2010]
Comparison of parenteral iron sucrose and ferric chloride during erythropoietin
therapy of haemodialysis patients. [2010]
Blood transfusion reduction with intravenous iron in gynecologic cancer patients
receiving chemotherapy. [2010]
Maintenance of elevated versus physiological iron indices in non-anaemic patients
with chronic kidney disease: a randomized controlled trial. [2010]
Intravenous iron in inflammatory bowel disease. [2009.10.07]
A randomized, double-blind, placebo controlled, multi-center study of intravenous iron sucrose and placebo in the treatment of restless legs syndrome. [2009.07.30]
Comparison of serum ferritin and transferrin saturation values associated with two i.v. iron formulations in hemodialysis patients. [2009.06.15]
|
